Expression of serum Hsa-miR-93 in uterine cancer and its clinical significance.

The aim of the study was to investigate the differential expression of micro-ribonucleic acid (miRNA)-93 in serum of patients with uterine cancer, and to explore the clinical significance. A total of 176 patients with uterine cancer who received surgery from May, 2009 to January, 2011 in the Department of Oncology of Hubei Cancer Hospital were selected. At the same time, 100 healthy individuals selected from the Physical Examination Center of Hubei Cancer Hospital comprised the control group. Mean age of patients was 55±11 years, and of the healthy individuals in the control group was 53±9 years. Blood was extracted from each participant to prepare serum samples. Change in the expression of serum miRNA-93 was detected by reverse transcription-polymerase chain reaction (RT-PCR), and the correlation between the expression of miRNA-93 and clinicopathological features of uterine cancer was analyzed. Expression level of miRNA-93 in serum of patients with uterine cancer was significantly lower than that in the healthy controls (P<0.05). Expression level of miRNA-93 was significantly correlated with pathological staging and lymph node metastasis (P<0.05). Receiver operating characteristic curve analysis showed that the area under curve was 0.781 and 95% confidence interval was 0.724-0.842. Survival rate of the high miRNA-93 expression group was significantly higher than that in the low miRNA-93 expression group (P=0.036). These results indicate that change in the expression of miRNA-93 is related to the occurrence of uterine cancer, and its decreased expression level suggests tumorigenesis.